Literature DB >> 24106728

Minimal hepatic encephalopathy.

Laura M Stinton, Saumya Jayakumar.   

Abstract

Minimal hepatic encephalopathy (MHE) is the earliest form of hepatic encephalopathy and can affect up to 80% of cirrhotic patients. By definition, it has no obvious clinical manifestation and is characterized by neurocognitive impairment in attention, vigilance and integrative function. Although often not considered to be clinically relevant and, therefore, not diagnosed or treated, MHE has been shown to affect daily functioning, quality of life, driving and overall mortality. The diagnosis of MHE has traditionally been achieved through neuropsychological examination, psychometric tests or the newer critical flicker frequency test. A new smartphone application (EncephalApp Stroop Test) may serve to function as a screening tool for patients requiring further testing. In addition to physician reporting and driving restrictions, medical treatment for MHE includes non-absorbable disaccharides (eg, lactulose), probiotics or rifaximin. Liver transplantation may not result in reversal of the cognitive deficits associated with MHE.

Entities:  

Mesh:

Year:  2013        PMID: 24106728      PMCID: PMC3805337          DOI: 10.1155/2013/547670

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  34 in total

1.  Is minimal hepatic encephalopathy completely reversible following liver transplantation?

Authors:  Christopher Rose; Rajiv Jalan
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

Review 2.  Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations.

Authors:  María Ortiz; Carlos Jacas; Juan Córdoba
Journal:  J Hepatol       Date:  2004-12-28       Impact factor: 25.083

Review 3.  Characteristics of minimal hepatic encephalopathy.

Authors:  Piero Amodio; Sara Montagnese; Angelo Gatta; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

4.  Fitness to drive in patients with cirrhosis and portal-systemic shunting: a pilot study evaluating driving performance.

Authors:  A Srivastava; R Mehta; S P Rothke; A W Rademaker; A T Blei
Journal:  J Hepatol       Date:  1994-12       Impact factor: 25.083

5.  Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability.

Authors:  A Watanabe; T Tuchida; Y Yata; Y Kuwabara
Journal:  Metab Brain Dis       Date:  1995-09       Impact factor: 3.584

6.  Prognostic significance of hepatic encephalopathy in patients with cirrhosis.

Authors:  J Bustamante; A Rimola; P J Ventura; M Navasa; I Cirera; V Reggiardo; J Rodés
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

Review 7.  Review article: the burden of hepatic encephalopathy.

Authors:  F F Poordad
Journal:  Aliment Pharmacol Ther       Date:  2007-02       Impact factor: 8.171

8.  Minimal hepatic encephalopathy impairs fitness to drive.

Authors:  Christian Wein; Horst Koch; Birthe Popp; Gerd Oehler; Peter Schauder
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

9.  Subclinical hepatic encephalopathy impairs daily functioning.

Authors:  M Groeneweg; J C Quero; I De Bruijn; I J Hartmann; M L Essink-bot; W C Hop; S W Schalm
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

10.  Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis.

Authors:  Qing Liu; Zhong Ping Duan; Da Kang Ha; Stig Bengmark; Jelica Kurtovic; Stephen M Riordan
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

View more
  14 in total

1.  Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis.

Authors:  Henry H Nguyen; Mark G Swain; Philip Wong; Stephen E Congly
Journal:  CMAJ Open       Date:  2018-12-03

Review 2.  PET and MR imaging of neuroinflammation in hepatic encephalopathy.

Authors:  Yun Yan Su; Gui Fen Yang; Guang Ming Lu; Shawn Wu; Long Jiang Zhang
Journal:  Metab Brain Dis       Date:  2014-12-17       Impact factor: 3.584

3.  Intracortical inhibitory and excitatory circuits in subjects with minimal hepatic encephalopathy: a TMS study.

Authors:  Raffaele Nardone; Pierpaolo De Blasi; Yvonne Höller; Francesco Brigo; Stefan Golaszewski; Vanessa N Frey; Andrea Orioli; Eugen Trinka
Journal:  Metab Brain Dis       Date:  2016-06-02       Impact factor: 3.584

4.  Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.

Authors:  Meghan NeSmith; Joseph Ahn; Steven L Flamm
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-02

Review 5.  Palliative care for patients with end-stage liver disease.

Authors:  Anne M Larson
Journal:  Curr Gastroenterol Rep       Date:  2015-05

Review 6.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

7.  Cognitive dysfunction and hepatitis C virus infection.

Authors:  Antonio Solinas; Maria Rita Piras; Angelo Deplano
Journal:  World J Hepatol       Date:  2015-05-08

8.  Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Cross-Sectional, Clinicoepidemiological, Multicenter, Nationwide Study in India: The PREDICT Study.

Authors:  Sahaj Rathi; Madhu Chopra; Gourdas Chouduri; Praveen Sharma; Kaushal Madan; Mohinish Chhabra; Ramesh R Rai; Anurag Govil; Asokananda Konar; Mahesh Goenka; Manoj Agarwal; Jayanta Mukherjee; Vinay Thorat; Sanjay Salunkhe; Philip Abraham; Aabha Nagral; Ajay Jhaveri; Naresh Bhat; Joy Varghese; Arun R S; Deevaguntla C Reddy; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2018-10-15

9.  Frequency of minimal hepatic encepalopathy in illeterate patients with compensated cirrhosis.

Authors:  Bader Faiyaz Zuberi; Haris Alvi; Faisal Faiyaz Zuberi; Tazeen Rasheed; Zunaira Nawaz
Journal:  Pak J Med Sci       Date:  2016 May-Jun       Impact factor: 1.088

10.  Normalisation of the psychometric encephalopathy score within the Cameroonian population.

Authors:  Larissa Pessidjo Djomatcho; Mathurin Pierre Kowo; Antonin Ndjitoyap Ndam; Sylvain Raoul Simeni Njonnou; Gabin Ulrich Kenfack; Firmin Ankouane Andoulo; Servais Fiacre Eloumou Bagnaka; Winnie Tatiana Bekolo; Agnès Malongue; Isabelle Dang Babagna; Magloire Biwolé Sida; Henry Luma; Oudou Njoya
Journal:  BMC Gastroenterol       Date:  2021-07-12       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.